ESH AL 2018 | FLT3 inhibitors in the treatment of AML
Farhad Ravandi
Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, describes which FLT3 inhibitors his group uses to treat different subsets of patients with acute myeloid leukemia (AML ). This video was recorded at the 2018 European School of Hematology (ESH) Clinical Updates on Acute Leukemias, held in Budapest, Hungary.
Related videos
An exciting era for CAR T-cell therapy
Mohamad Mohty
Anti-CD19 CAR T-cell therapy in combination with ibrutinib for CLL/SLL
Saar Gill
Ibrutinib combinations for CLL: iLLUMINATE results & more
Carol Moreno
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
Combining novel agents for CLL to achieve deep remissions: time-limited therapy, treatment cessation & drug re-use in relapse
Talha Munir
